[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"propranolol\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:propranolol":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,50,83],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":32,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":4},"100648929","phase-1-neoadjuvant-propranolol-plus-sox-and-toripalimab-for-locally-advanced-gastricgej-adenocarcinoma-100648929",false,"NCT07727993","Neoadjuvant Propranolol Plus SOX and Toripalimab for Locally Advanced Gastric\u002FGEJ Adenocarcinoma","A Prospective, Open-Label, Single-Arm, Phase Ib\u002FII Study of Neoadjuvant Propranolol Plus SOX Chemotherapy and Toripalimab in Patients With Resectable Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma","Inclusion Criteria:\n\n1. Voluntary participation in the study, with written informed consent, and willingness and ability to comply with the study treatment and follow-up requirements.\n2. Male or female participants aged 18 to 75 years.\n3. Histologically or cytologically confirmed gastric or gastroesophageal junction adenocarcinoma.Resectable locally advanced disease as determined by imaging assessment or a multidisciplinary team according to the eighth edition of the American Joint Committee on Cancer staging system, generally defined as cT3-4a with any N category, or any T category with node-positive disease, corresponding to stage II-III disease, without distant metastasis.\n4. Eastern Cooperative Oncology Group performance status of 0 or 1.\n5. Acceptable cardiopulmonary function, including all of the following:\n\n(1)No clinically significant abnormality on electrocardiography; (2)Resting heart rate of at least 60 beats per minute; (3)Systolic blood pressure of at least 90 mmHg; (4)No progressive or decompensated cardiopulmonary disease; (5)Left ventricular ejection fraction of at least 50%. 6.Adequate organ function during screening, defined as follows:\n\n1. Absolute neutrophil count of at least 1.5 × 10⁹\u002FL;\n2. Platelet count of at least 75 × 10⁹\u002FL;\n3. Hemoglobin level of at least 90 g\u002FL;\n4. Total bilirubin no greater than 1.5 times the upper limit of normal;\n5. Aspartate aminotransferase and alanine aminotransferase no greater than 2.5 times the upper limit of normal;\n6. Serum creatinine no greater than 1.5 times the upper limit of normal or creatinine clearance of at least 50 mL\u002Fmin;\n7. International normalized ratio no greater than 1.5 times the upper limit of normal, unless the participant is receiving stable anticoagulation and is considered eligible by the investigator.\n\n7.Female participants of childbearing potential must have a negative pregnancy test during screening. Male and female participants of reproductive potential must agree to use effective contraception during the study and for at least 6 months after the last dose of study treatment.\n\nExclusion Criteria:\n\n1. Distant metastatic disease confirmed by imaging or diagnostic laparoscopy, including but not limited to peritoneal, hepatic, or bone metastases, or positive peritoneal cytology.\n2. Previous systemic anticancer treatment for the current malignancy, including chemotherapy, immunotherapy, or targeted therapy, or previous radiotherapy. Diagnostic endoscopy and biopsy are permitted.\n3. Grade 2 or higher peripheral neuropathy at baseline.\n4. A second primary malignancy requiring systemic treatment within the previous 3 years, except for adequately treated basal cell or squamous cell carcinoma of the skin, carcinoma in situ of the cervix, low-risk thyroid cancer, or other malignancies considered cured.\n5. Inability to tolerate curative-intent surgery or study treatment, as determined by the investigator.\n6. Active autoimmune disease, or a clinically significant history of autoimmune disease requiring systemic immunosuppressive treatment within the previous 2 years. Participants with type 1 diabetes mellitus, stable thyroid disease requiring replacement therapy, vitiligo, or grade 2 or lower psoriasis not requiring systemic treatment may be eligible.\n7. Use of systemic corticosteroids at a prednisone-equivalent dose of at least 10 mg\u002Fday, or other systemic immunosuppressive agents, within 14 days before the planned initiation of immunotherapy. Physiologic replacement therapy, inhaled or topical corticosteroids, and short-term prophylactic treatment related to surgery are permitted.\n8. Active infection, including but not limited to active tuberculosis, uncontrolled hepatitis B virus or hepatitis C virus infection, human immunodeficiency virus infection, or another serious infection requiring intravenous antibiotic treatment.\n9. Any contraindication to propranolol, including:\n\n(1)Bronchial asthma or a risk of bronchospasm; (2)Diabetic ketoacidosis or metabolic acidosis; (3)Severe or symptomatic bradycardia; (4)Second- or third-degree atrioventricular block, sinoatrial block, or sick sinus syndrome; (5)Cardiogenic shock; (6)Right-sided heart failure caused by pulmonary hypertension; (7)Congestive heart failure; (8)Clinically significant hypotension; (9)Prolonged fasting; (10)Severe peripheral circulatory failure; (11)Untreated pheochromocytoma; (12)Variant angina; (13)Concomitant treatment with rizatriptan benzoate. 10.Moderate or severe chronic obstructive pulmonary disease with a recent acute exacerbation.\n\n11.Active upper gastrointestinal bleeding at baseline, melena or hematemesis within the previous 4 weeks, bleeding requiring blood transfusion or endoscopic hemostasis, uncontrolled peptic ulcer disease, or a high risk of recent bleeding as determined by the investigator.\n\n12.Requirement for continuous full-dose anticoagulation, dual antiplatelet therapy that cannot be interrupted, or a bleeding disorder that cannot be adequately managed during the perioperative period.\n\n13.Known hypersensitivity to propranolol, oxaliplatin, S-1 or fluoropyrimidines, toripalimab, or any of their excipients, or a history of a severe adverse reaction to any of these agents.\n\n14.Concomitant use of medications that cannot be discontinued or replaced and that may cause clinically significant interactions with propranolol, including verapamil, diltiazem, class I or class III antiarrhythmic agents, strong CYP2D6 or CYP1A2 inhibitors, or other medications considered by the investigator to pose a major drug-drug interaction risk.\n\n15.Uncontrolled bleeding disorder, or major surgery or serious trauma within 4 weeks before enrollment, excluding the curative-intent surgery planned as part of this study.\n\n16.Pregnancy or breastfeeding, or unwillingness to use the required contraceptive measures.\n\n17.Any medical, psychiatric, social, or other condition that, in the investigator's judgment, may compromise participant safety, treatment compliance, or completion of the required follow-up, including severe psychiatric illness, substance abuse, or inability to attend scheduled visits.","ALL","18 Years","75 Years",{"count":20,"type":21},49,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE1","PHASE2","This is a single-center, prospective, open-label, single-arm, phase Ib\u002FII study evaluating the safety and efficacy of neoadjuvant propranolol combined with SOX chemotherapy and toripalimab in patients with resectable locally advanced gastric or gastroesophageal junction adenocarcinoma. A total of 49 participants will be enrolled. Stage 1 includes an initial safety lead-in of 12 participants, followed by efficacy evaluation using a Simon two-stage design. Participants will receive propranolol, toripalimab, oxaliplatin, and S-1 during the neoadjuvant period, followed by curative-intent surgery.\n\nThe primary efficacy endpoint is pathological complete response. Secondary endpoints include safety and tolerability, major pathological response, R0 resection rate, event-free survival, recurrence-free survival, and overall survival. Exploratory analyses will assess changes in adrenergic stress markers, heart rate variability, peripheral immune parameters, β-adrenergic receptor signaling, and the tumor immune microenvironment.",[28,29,30,31],"Gastric or Gastroesophageal Junction Adenocarcinoma","Propranolol","SOX Chemotherapy","Toripalimab",[33,34,35,36,37],"gastric or gastroesophageal junction adenocarcinoma","propranolol","OX chemotherapy","toripalimab","neoadjuvant therapy","NOT_YET_RECRUITING","2026-07-22",{"date":41,"type":42},"2026-07-27","ACTUAL",{"date":44,"type":21},"2026-08-01",{"date":46,"type":21},"2027-12-31",{"name":48,"class":49},"Ting Liu","OTHER",{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":57,"sex":58,"minAge":59,"maxAge":60,"enrollmentInfo":61,"targetDuration":4,"studyType":22,"phases":63,"briefSummary":65,"conditions":66,"keywords":68,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":82},"100589933","effects-of-oral-propranolol-on-induction-delivery-interval-during-induction-of-labour-with-oxytocin-100589933","NCT06960850","Effects of Oral Propranolol on Induction-Delivery Interval During Induction of Labour With Oxytocin","A Randomized Controlled Trial on the Effect of Oral Propranolol on Induction-Delivery Interval in Women Undergoing Oxytocin Induction of Labour in Abakaliki","Inclusion Criteria:\n\n* singleton foetus\n* cephalic presentation at term\n\nExclusion Criteria:\n\n* Patients on beta blockers\n* Contraindications to labour or vaginal delivery\n* Multiple gestations\n* Preterm labour\n* Chorioamnionitis\n* Known fetal anomalies\n* Bronchial asthma\n* Abnormal fetal presentation.\n* Antepartum haemorrhage.\n* Lung disease\n* Previous uterine scar or surgery.\n* Foetal heart irregularity",true,"FEMALE","15 Years","45 Years",{"count":62,"type":21},308,[64],"NA","Prolonged pregnancy could lead to perinatal and maternal complications. Oxytocin has been wildly used for induction of labour, but prolonged labour continued to occur with its attendant sequelae. Propranolol, a non-selective B-adrenergic inhibitor has been found to facilitate labour progress in some studies, by the blockade of the effects of catecholamines on the uterus though there are conflicting reports, with the only meta-analysis inconclusive due to few studies used; hence, the need to further study its role in induction of labour. The aim of this study is to assess the role of oral Propranolol in decreasing the induction-delivery with oxytocin",[29,67],"Labour Induction",[69,70,71,67],"Propanolol","Induction-Delivery","Oxytocin","2025-04-29",{"date":74,"type":42},"2025-05-07",{"date":76,"type":21},"2025-06-01",{"date":78,"type":21},"2025-12-01",{"name":80,"class":81},"Federal Teaching Hospital Abakaliki","OTHER_GOV",1,{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":89,"eligibilityCriteria":90,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":91,"targetDuration":4,"studyType":22,"phases":93,"briefSummary":94,"conditions":95,"keywords":4,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":82},"100514539","phase-1-propranolol-hydrochloride-in-combination-with-sintilimab-and-platinum-based-chemotherapy-for-treatment-of-advanced-non-small-cell-lung-cancer-100514539","NCT05979818","Propranolol Hydrochloride in Combination With Sintilimab and Platinum-based Chemotherapy for Treatment of Advanced Non-small Cell Lung Cancer","Study of Propranolol Hydrochloride in Combination With Sintilimab and Platinum-based Chemotherapy for Treatment of Advanced Non-small Cell Lung Cancer (BRIO)","BRIO","Inclusion Criteria:\n\n* Sign a written informed consent prior to any research-related procedure\n* Age ≥18 years and ≤ 75 years old\n* ECOG PS score of 0-1\n* Expected survival time ≥ 12 weeks\n* Patients with histologically or cytologically confirmed non-localizable stage IIIB-IIIC, stage IV non-small cell lung cancer (International Association for the Study of Lung Cancer and the Joint Committee on the American Classification of Cancers, 8th edition). Patients with unresectable IIIB-IIIC include recurrent and primary unresectable (surgery and radical concurrent chemoradiotherapy), and stage IV includes primary or recurrent stage IV but without prior systemic therapy for advanced\u002Fmetastatic disease.\n* Chemotherapy and chemoradiotherapy are permitted as neoadjuvant\u002Fadjuvant treatment as long as the treatment is completed at least 12 months prior to the diagnosis of advanced or metastatic disease\n* There must be no EGFR gene-sensitive mutation, ALK gene fusion or ROS1 gene fusion in non-squamous carcinoma\n* At least one imaging measurable lesion according to the criteria for the evaluation of the efficacy of solid tumors (RECIST version 1.1). A lesion located in the field of exposure to previous radiotherapy is considered measurable if progression is confirmed (within 28 days prior to the first treatment)\n* Subjects with brain metastases who are asymptomatic or whose symptoms have stabilized with local treatment are permitted to be enrolled, provided that the subject meets the following criteria:\n\n  1. Have a measurable lesion outside the CNS.\n  2. No CNS symptoms or no worsening of symptoms for at least 2 weeks.\n  3. No glucocorticoid therapy is required, or glucocorticoid therapy has been discontinued within 7 days prior to the first dose, or the glucocorticoid dosage has been stable and reduced to less than 10 mg\u002Fday of prednisone (or equivalent dose) within 7 days prior to the first dose\n* Meet the following laboratory indicators (within 14 days before the first treatment):\n\n  1. Blood routine examination: absolute neutrophil count ≥ 1.5 x 10\\^9\u002FL; platelet count ≥ 100 x 10\\^9\u002FL; hemoglobin level ≥ 9.0 g\u002FdL (no blood transfusion or erythropoietin-dependent administration within 7 days).\n  2. Liver function: total bilirubin (TBIL) ≤ 1.5 × upper limit of normal (ULN); alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN in the absence of hepatic metastases; ALT or AST ≤ 5 × ULN in the case of patients with hepatic metastases.\n  3. Renal function: serum creatinine (Cr) ≤1.5 times ULN or Cr clearance ≥60 mL\u002Fmin (Cockcroft-Gault formula), and urine routine test results show urine protein (UPRO) \\\u003C2+ or 24-hour urine protein quantification \\\u003C1g.\n  4. Coagulation: International Normalized Ratio (INR) ≤ 1.5 times ULN or Prothrombin Time (PT) ≤ 1.5 times ULN within 7 days prior to study treatment; if the subject is receiving anticoagulant therapy, as long as the PT is within the range of the anticoagulant drug\n* Heart function: the New York heart association (NYHA) classification \\\u003C 3;Left ventricular ejection fraction（LVEF）≥ 50%; Baseline ECG showed no PR interval lengthened or atrioventricular block\n* For female subjects of childbearing potential, a negative urine or serum pregnancy test should be obtained within 3 days prior to receiving the first dose of study drug (Day 1 of Cycle 1). If a negative urine pregnancy test result cannot be confirmed, a blood pregnancy test will be requested. Females not of childbearing potential are defined as being at least 1 year postmenopausal or having undergone surgical sterilization or hysterectomy; if conception is at risk, all subjects (male or female) are required to use contraception with an annual failure rate of less than 1% throughout the treatment period up to 120 days after the end-of-treatment administration of study drug (or 180 days after the end-of-study drug administration)\n\nExclusion Criteria:\n\n* Concurrent participation in another interventional clinical study or receipt of another investigational drug, unless participating in an observational clinical study\n* Prior exposure to any anti-PD-1 or anti-PD-L1, PD-L2, CD137, CTLA-4 antibody therapy, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways\n* Systemic therapy with proprietary Chinese medicines with anti-tumor indications or immunomodulatory drugs (including thiopeptides, interferons, interleukins, except those used locally for the control of hydrothorax or ascites) within 2 weeks prior to the first dose\n* Current use of oral or intravenous beta-blockers (e.g., atenolol, bisoprolol, carvedilol, labetalol, metoprolol, nadolol, sotalol, etc.) cannot be safely switched to a non-beta-blocker\n* There are contraindications to the use of beta-blockers:\n\n  1. Hypersensitivity to any of the components of the product.\n  2. Bronchial asthma or risk of bronchospasm.\n  3. Ketoacidosis and metabolic acidosis.\n  4. Severe or symptomatic bradycardia (resting heart rate ≤55bpm), atrioventricular block (degrees II and III), sinus block, sick sinus node syndrome.\n  5. Cardiogenic shock\n  6. Right heart insufficiency due to pulmonary hypertension.\n  7. Congestive heart failure (class III or IV).\n  8. Hypotension (systolic blood pressure \\\u003C 100 mmHg).\n  9. Prolonged fasting.\n  10. Severe peripheral circulatory failure (e.g., gangrene).\n  11. Symptomatic peripheral arterial disease or Raynaud's syndrome, untreated pheochromocytoma.\n  12. Unstable angina or variant angina.\n  13. Patients on rizatriptan benzoate.\n  14. Severe asthma or chronic obstructive pulmonary disease (COPD)\n  15. Uncontrolled type I or type II diabetes mellitus (glycosylated hemoglobin \\[HbA1C\\] \\> 8.5 or fasting blood glucose \\> 160 mg\u002Fdl at screening).\n  16. Current use or within the last 2 years of a non-dihydropyridine calcium channel blocker (NDCCB)\n* Hepatic encephalopathy, hepatorenal syndrome or Child-Pugh class B or more severe cirrhosis\n* Tumor-related intestinal obstruction (within 3 months prior to the signing of the informed consent) or history of inflammatory bowel disease or extensive bowel resection (partial colectomy or extensive small bowel resection with chronic diarrhea), Crohn's disease, ulcerative colitis\n* Completion of palliative radiotherapy within 7 days prior to the first dose of study drug\n* With clinically active diverticulitis, abdominal abscess, gastrointestinal obstruction\n* History of psychotropic substance abuse or addiction\n* Known hypersensitivity to the active ingredients or excipients of the study drug\n* Known history of primary immunodeficiency or undergoing systemic glucocorticoid therapy or any other form of immunosuppressive therapy\n* Use of immunosuppressive drugs, excluding topical glucocorticoids by nasal, inhalational or other routes or physiological doses of systemic glucocorticoids (i.e., no more than 10 mg\u002Fday of prednisone or an equivalent dose of other glucocorticoids), or use of hormones for the prevention of contrast sensitization, within 4 weeks prior to the first dose of study treatment\n* Failure to recover adequately from any intervention-induced toxicity and\u002For complications (≤ grade 1 or baseline, excluding weakness or alopecia) prior to initiation of treatment\n* Receipt of live attenuated influenza vaccine within 4 weeks prior to the first dose of study treatment or planned for the duration of the study (inactivated injectable viral vaccine against seasonal influenza is permitted up to 4 weeks prior to the first dose; however, live attenuated influenza vaccine is not permitted)\n* Major surgery (craniotomy, thoracotomy, or laparotomy) within 4 weeks prior to the first dose of study treatment or anticipation of major surgery during study treatment; laparoscopic exploratory surgery within 2 weeks prior to the first dose of study treatment\n* Known symptomatic CNS metastases and\u002For carcinomatous meningitis. Subjects with previously treated brain metastases may be enrolled in the trial if they are clinically stable (no evidence of imaging progression for at least 4 weeks prior to the first dose of the experimental treatment, no evidence of new brain metastases or increase in size of pre-existing brain metastases as confirmed by repeat imaging) and do not require steroid therapy for at least 14 days prior to the first dose of the experimental treatment. This exception does not include carcinomatous meningitis, which should be excluded regardless of whether it is clinically stable.\n* Presence of clinically uncontrolled pleural effusion or ascites (subjects may be recruited who do not require drainage of the effusion or who do not have a significant increase in the effusion after 3 days of cessation of drainage)\n* Patients with bone metastases at risk of paraplegia\n* Known or suspected autoimmune disease or history of such disease within the last 2 years (patients with vitiligo, psoriasis, alopecia areata or Graves' disease not requiring systemic treatment within the last 2 years, hypothyroidism requiring only thyroid hormone replacement therapy, and type I diabetes mellitus requiring only insulin replacement therapy may be enrolled)\n* Known to have active tuberculosis.\n* A history of allogeneic organ transplants and allogeneic hematopoietic stem cell transplants is known\n* Known history of human immunodeficiency virus (HIV) infection (HIV-positive)\n* Known acute or chronic active hepatitis B virus (HBsAg-positive and HBVDNA viral load ≥200 IU\u002FmL or ≥10\\^3 copies\u002FmL) or acute or chronic active hepatitis C virus (HCV antibody-positive and HCV RNA-positive)\n* Active syphilis infection requiring treatment\n* Suffer from interstitial lung disease requiring steroid hormone therapy\n* Serious infections that are active or poorly controlled clinically\n* Severe cardiovascular disease (e.g., myocardial infarction, arterial thromboembolism, cerebrovascular thromboembolism); angina pectoris requiring treatment; symptomatic peripheral vascular disease; NYHA cardiac class 3 or 4 congestive heart failure; or uncontrolled ≥class 3 hypertension (diastolic blood pressure ≥100 mm Hg or systolic blood pressure ≥160 mm Hg) despite antihypertensive treatment\n* History of other primary malignancies within 5 years, except：\n\n  1. malignancies that have been in complete remission for at least 2 years prior to enrolment and for which no other treatment was required during the study period.\n  2. adequately treated non-melanoma skin cancer or malignant nevus with no evidence of disease recurrence.\n  3. adequately treated carcinoma in situ without evidence of disease recurrence\n* Female patients who are pregnant or breastfeeding\n* Other acute or chronic medical conditions, psychiatric disorders, or abnormal laboratory test values that may result in increased risk associated with study participation or administration of study medication, or interfere with the interpretation of study results, and that, in the investigator's judgement, classify the patient as ineligible for participation in this study.",{"count":92,"type":21},6,[24],"This study is a prospective single-center Phase I clinical study in patients with EGFR\u002FALK\u002FROS1 driver oncogene negative, and advanced or metastatic NSCLC. This study is to evaluate the efficacy and safety preliminarily in a small-size of propranolol hydrochloride in combination with sintilimab and platinum-based chemotherapy in first-line therapy. Propranolol hydrochloride is a beta- adrenergic blocking agent which is associated with augment of immune cell responses. Propranolol hydrochloride may improve the responses of immune checkpoint inhibitors in treating patients with advanced NSCLC.",[96,29],"Non Small Cell Lung Cancer","RECRUITING","2024-11-14",{"date":100,"type":42},"2024-11-19",{"date":102,"type":42},"2024-11-13",{"date":104,"type":21},"2026-12-31",{"name":106,"class":49},"Second Xiangya Hospital of Central South University"]